CELULARITY INC Reported Earnings

CELULARITY INC (CELU) reported a loss of $0.12 per share on revenue of $5.43 million for the . . Revenue fell 5.30% compared to the same quarter a year ago.

Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious and degenerative diseases. Celularity Inc., formerly known as GX Acquisition Corp., is based in NEW YORK.